Nadofaragene firadenovec, an adenovirus vector-based gene therapy containing the gene interferon alfa-2b, achieved a complete response in 53% of patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease at 3 months.
Investigators report encouraging findings from a novel active surveillance management approach for patients with small renal masses.
In a phase 2 trial, patients with high-risk UTUC who had a complete radiographic response after neoadjuvant chemotherapy were more likely to have a pathologic response at surgery.
New study finds comparable rates of complications and overall, cancer-specific, and metastasis-free survival rates.
Compared with TRUS biopsies, MRI fusion biopsy findings are more likely to be concordant with final prostate cancer pathology at the time of radical prostatectomy, a study found.
Investigators report finding no significant difference in biochemical recurrence-free and metastasis-free survival and freedom from treatment between men with very-low-risk and low-risk prostate cancer and those with favorable intermediate-risk disease.
New prediction tools may inform the likelihood of downgrading, favorable pathology, or upgrading in intermediate-risk or low-risk prostate cancer patients.
Study finds that prostate cancer patients with PSA levels of 50 ng/mL or higher prior to radical prostatectomy have a 20-year cancer-specific mortality rate of 20.5%.
In a study of men who received sipuleucel-T immunotherapy for metastatic castration-resistant prostate cancer, a PSA level below 5 ng/mL at baseline was associated with significantly longer survival compared with a higher PSA level.
Study findings suggest that pT0 response can be attributed not only to neoadjuvant chemotherapy, but also to high-quality transurethral resections.
